Previous close | 0.2400 |
Open | 0.2300 |
Bid | 0.0500 |
Ask | 0.3000 |
Strike | 90.00 |
Expiry date | 2025-01-17 |
Day's range | 0.2300 - 0.2400 |
Contract range | N/A |
Volume | |
Open interest | 2.39k |
U.S. National Institutes of Health has launched two clinical trials to examine a novel long-acting form of HIV pre-exposure prophylaxis (PrEP) in cisgender women and people who inject drugs. The mid-stage studies will assess the safety, acceptability, and pharmacokinetics (how a drug moves through the body) of lenacapavir, an antiretroviral drug administered by injection every six months. Gilead Sciences Inc. (NASDAQ:GILD) sponsored and funded the studies implemented through the HIV Prevention T
NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR are part of the Zacks top Analyst Blog.
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss Gilead Sciences, Inc. (NASDAQ:GILD), which is one of the best gene therapy stocks to buy now. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. […]